References

Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J Educ Health Promot.. 2014; 3 https://doi.org/10.4103/2277-9531.127541

Bersoux S, Byun TH, Chaliki SS, Poole KG. Pharmacotherapy for obesity: what you need to know. Cleve Clin J Med.. 2017; 84:(12)951-958 https://doi.org/10.3949/ccjm.84a.16094

Approval of drug is “major regression for patients' safety,” says health watchdog. 2014. www.bmj.com/bmj/section-pdf/863495?path=/bmj/350/7989/News.full.pdf

British National Formulary. Home. 2018. https://bnf.nice.org.uk (accessed 6 August 2019)

European Association for the Study of Obesity. A statement of the members of the European Association for the Study of Obesity to EXPO 2015. 2015. https://easo.org/2015-milan-declaration-a-call-to-action-on-obesity/ (accessed 6 August 2019)

European Medicines Agency. Guideline on clinical evaluation of medicinal products used in weight control. 2014. https://tinyurl.com/y4npqwvc (accessed 6 August 2019)

European Medicines Agency. Saxenda recommended for approval in weight management in adults. 2015. https://tinyurl.com/yyawwlqv (accessed 6 August 2019)

Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev.. 2007; 87:1409-1439 https://doi.org/10.1152/physrev.00034.2006

Jarolimova J, Tagoni J, Stern T. Obesity: its epidemiology, comorbidities, and management. Prim Care Companion CNS Disord.. 2013; 15:(5) https://doi.org/10.4088/PCC.12f01475

Knowler WC, Barrett-Connor E, Fowler SE Reduction in the Incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med.. 2002; 346:(6)393-403

Ladenheim E. Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther.. 2015; 9:1867-1875 https://doi.org/10.2147/DDDT.S58459

Lean ME, Carraro R, Finer N Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond). 2014; 38:689-697

Li G, Zhang P, Wang J Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol.. 2014; 2:(6)474-480 https://doi.org/10.1016/S2213-8587(14)70057-9

Medicines.org.uk. Saxenda. 2019. https://www.medicines.org.uk/emc/product/2313/smpc (accessed 14 August 2019)

National Institute for Health and Care Excellence. Orlistat. 2019a. https://bnf.nice.org.uk/drug/orlistat.html (accessed 6 August 2019)

National Institute for Health and Care Excellence. Naltrexone with bupropion. 2019b. https://bnf.nice.org.uk/drug/orlistat.html (accessed 6 August 2019)

National Institute for Health and Care Excellence. Liraglutide. 2019c. https://bnf.nice.org.uk/drug/liraglutide.html (accessed 6 August 2019)

Organisation for Economic Co-operation and Development. Obesity update. 2014. www.oecd.org/health/Obesity-Update-2014.pdf (accessed 6 August 2019)

Pi-Sunyer X, Astrup A, Fujioka K A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med.. 2015; 373:(1)11-22 https://doi.org/10.1056/NEJMoa1411892

Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss. Prescrire Int.. 2015; 24:(164)229-33

Scarborough P, Bhatnagar P, Wickramasinghe KK The economic burden of ill health due to diet, physical inactivity, smoking, alcohol and obesity in the UK: an update to 2006/07 NHS costs. J Public Health (Oxon). 2011; 33:(4)527-535

Wadden TA, Hollander P, Klein S Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2015; 39:(1)

Warkentin LM, Majumdar SR, Johnson JA Predictors of health-related quality of life in 500 severely obese patients. Obesity. 2014; 22:(5)1367-1372 https://doi.org/10.1002/oby.20694

Wing RR, Lang W, Wadden TA Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34:(7)1481-1486 https://doi.org/10.2337/dc10-2415

World Health Organization. Obesity: preventing and managing the global epidemic. 2000. www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/ (accessed 6 August 2019)

World Health Organization. Obesity and overweight. 2019. www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed 6 August 2019)

The role of liraglutide in the management of obesity

02 September 2019
Clinical
02 September 2019
Volume 8 · Issue 7

Abstract

Obesity has been defined as abnormal or excessive fat accumulation that may impair health. Obesity is associated with multiple comorbidities, affecting mechanical systems within the body as well as metabolic and mental health. If a person is overweight or obese, a loss of 5–10% of total body weight can have a number of health advantages. In the UK, there are three medications approved by the European Medicines Agency (EMA) for weight loss: orlistat, liraglutide and naltrexone in combination with bupropion. Liraglutide has the proprietary name Saxenda (Novo Nordisk). It may be prescribed for individuals with a body mass index (BMI) of 30 kg/m2 or more or people with a BMI of 27 kg/m2 who have another weight-related illness, such as high blood pressure, type 2 diabetes or dyslipidaemia. As with many weight-management programmes, liraglutide works in conjunction with a reduced-calorie diet and increased physical activity.

The World Health Organization (WHO) has defined obesity as abnormal or excessive fat accumulation that may impair health (WHO, 2000; 2019). The fundamental cause of obesity is an energy imbalance between calories consumed and calories expended. Globally, there has been an increased intake of energy-dense foods that are high in fat and carbohydrates, accompanied by a decrease in physical activity with increasingly sedentary lifestyles (WHO, 2019).

The most common and convenient measurement of obesity used is body mass index (BMI). BMI is calculated by dividing a person's weight in kilograms by their height in metres squared. The result produced then falls into a number of classifications (WHO, 2019). A BMI below 18.5 kg/m2 is classed as underweight, between 18.5 and 25 kg/m2 is considered healthy and between 25 and 30 kg/m2 is regarded as overweight. A BMI over 30 kg/m2 is classed as obese, with this range then being further divided into three obesity classes (Figure 1).

Register now to continue reading

Thank you for visiting Journal of Aesthetic Nurses and reading some of our peer-reviewed resources for aesthetic nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month

Register
Or continue by

Signing in with your registered email address

Bariatric
Obesity
Medication
Saxenda
Weight loss